Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice

Du, 2020, Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study, Biomark Res, 8, 1, 10.1186/s40364-020-00195-3 Padala, 2020, Epidemiology of Renal Cell Carcinoma, World J Oncol, 11, 79, 10.14740/wjon1279 Turajlic, 2018, Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal, Cell, 173, 581, 10.1016/j.cell.2018.03.057 Frew, 2015, A clearer view of the molecular complexity of clear cell renal cell carcinoma, Annu Rev Pathol, 10, 263, 10.1146/annurev-pathol-012414-040306 Delahunt, 2015, Renal neoplasia: From morphologic to molecular diagnosis, Semin Diagn Pathol, 32, 87, 10.1053/j.semdp.2015.02.001 Andeen, 2019, Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas, Arch Pathol Lab Med, 143, 494, 10.5858/arpa.2018-0104-OA Moch, 2016 Kryvenko, 2014, Diagnostic approach to eosinophilic renal neoplasms, Arch Pathol Lab Med, 138, 1531, 10.5858/arpa.2013-0653-RA Al-Ahmadie, 2008, Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies, Am J Surg Pathol, 32, 377, 10.1097/PAS.0b013e3181570343 Reuter, 2014, Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference, Am J Surg Pathol, 38, e35, 10.1097/PAS.0000000000000258 Smits, 2008, Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis, Clin Cancer Res, 14, 782, 10.1158/1078-0432.CCR-07-1753 2013, Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature, 499, 43, 10.1038/nature12222 Banks, 2006, Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer, Cancer Res, 66, 2000, 10.1158/0008-5472.CAN-05-3074 Beroukhim, 2009, Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney, Cancer Res, 69, 4674, 10.1158/0008-5472.CAN-09-0146 Adeniran, 2015, Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features, Am J Surg Pathol, 39, e1, 10.1097/PAS.0000000000000562 Trpkov, 2013, Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations, Am J Surg Pathol, 37, 1505, 10.1097/PAS.0b013e31829a85d0 Delahunt, 2019, Grading of renal cell carcinoma, Histopathology, 74, 4, 10.1111/his.13735 Delahunt, 2013, The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters, Am J Surg Pathol, 37, 1490, 10.1097/PAS.0b013e318299f0fb Kroeger, 2013, Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma, Cancer, 119, 1547, 10.1002/cncr.27947 Mitchell, 2018, Genomics and clinical correlates of renal cell carcinoma, World J Urol, 36, 1899, 10.1007/s00345-018-2429-x Liu, 2020, Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup, Cancer Genet, 244, 40, 10.1016/j.cancergen.2020.04.004 Sato, 2013, Integrated molecular analysis of clear-cell renal cell carcinoma, Nat Genet, 45, 860, 10.1038/ng.2699 Hakimi, 2015, TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype, Mod Pathol, 28, 845, 10.1038/modpathol.2015.6 Trpkov, 2019, New and emerging renal entities: a perspective post-WHO 2016 classification, Histopathology, 74, 31, 10.1111/his.13727 Lan, 2016, Unclassified renal cell carcinoma with tubulopapillary architecture, clear cell phenotype, and chromosome 8 monosomy: a new kid on the block, Virchows Arch, 469, 81, 10.1007/s00428-016-1952-7 Taylor, 2019, Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review, Arch Pathol Lab Med, 143, 1477, 10.5858/arpa.2019-0442-RA Rathmell, 2005, Renal cell carcinoma, Curr Opin Oncol, 17, 261, 10.1097/01.cco.0000155007.51495.d6 Rini, 2019, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Amin, 2008, Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases, Am J Surg Pathol, 32, 1822, 10.1097/PAS.0b013e3181831e68 Iczkowski, 2019, Eosinophilic Kidney Tumors: Old and New, Arch Pathol Lab Med, 143, 1455, 10.5858/arpa.2019-0203-RA Thoenes, 1985, Human chromophobe cell renal carcinoma, Virchows Arch B Cell Pathol Incl Mol Pathol, 48, 207, 10.1007/BF02890129 Tickoo, 2000, Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma, Am J Surg Pathol, 24, 1247, 10.1097/00000478-200009000-00008 Thoenes, 1988, Chromophobe cell renal carcinoma and its variants--a report on 32 cases, J Pathol, 155, 277, 10.1002/path.1711550402 Huo, 2005, C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas, Hum Pathol, 36, 262, 10.1016/j.humpath.2005.01.011 Carvalho, 2011, Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C-kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics, Histopathology, 58, 169, 10.1111/j.1365-2559.2011.03753.x Ng, 2016, A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma, J Clin Pathol, 69, 661, 10.1136/jclinpath-2015-203585 Michalova, 2020, Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture, Ann Diagn Pathol, 44, 151448, 10.1016/j.anndiagpath.2019.151448 Davis, 2014, The somatic genomic landscape of chromophobe renal cell carcinoma, Cancer Cell, 26, 319, 10.1016/j.ccr.2014.07.014 Casuscelli, 2017, Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma, JCI Insight, 2, 10.1172/jci.insight.92688 Amin, 2002, Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases, Am J Surg Pathol, 26, 281, 10.1097/00000478-200203000-00001 Steffens, 2014, The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma, Hum Pathol, 45, 2411, 10.1016/j.humpath.2014.08.002 Colomba, 2017, Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study, Eur J Cancer, 80, 55, 10.1016/j.ejca.2017.03.011 Przybycin, 2011, Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution, Am J Surg Pathol, 35, 962, 10.1097/PAS.0b013e31821a455d Paner, 2020, Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy?, Diagn Histopathol, 26, 320, 10.1016/j.mpdhp.2020.04.003 Suzigan, 2006, Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential, Am J Clin Pathol, 125, 217, 10.1309/AH6FC77PYR2V6YAY Gong, 2008, Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases, J Cancer Res Clin Oncol, 134, 433, 10.1007/s00432-007-0302-1 Li, 2016, Multilocular Cystic Renal Cell Neoplasm of Low Malignant Potential: A Series of 76 Cases, Clin Genitourin Cancer, 14, e553, 10.1016/j.clgc.2016.03.017 Tretiakova, 2018, Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum, Virchows Arch, 473, 85, 10.1007/s00428-018-2371-8 Westerman, 2019, Long-Term Outcomes of Patients with Low Grade Cystic Renal Epithelial Neoplasms, Urology, 133, 145, 10.1016/j.urology.2019.07.017 Halat, 2010, Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma, Mod Pathol, 23, 931, 10.1038/modpathol.2010.78 von Teichman, 2011, VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma, Mod Pathol, 24, 571, 10.1038/modpathol.2010.222 Williamson, 2012, Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma, Am J Surg Pathol, 36, 1425, 10.1097/PAS.0b013e31825b37f0 Tickoo, 2006, Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia, Am J Surg Pathol, 30, 141, 10.1097/01.pas.0000185382.80844.b1 Aydin, 2010, Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney, Am J Surg Pathol, 34, 1608, 10.1097/PAS.0b013e3181f2ee0b Gobbo, 2010, Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles, Am J Surg Pathol, 34, 620, 10.1097/PAS.0b013e3181d73293 Zhou, 2014, Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma, Hum Pathol, 45, 59, 10.1016/j.humpath.2013.08.004 Srigley, 2013, The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia, Am J Surg Pathol, 37, 1469, 10.1097/PAS.0b013e318299f2d1 Aron, 2015, Am J Surg Pathol, 39, 873, 10.1097/PAS.0000000000000446 Gobbo, 2008, Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis, Am J Surg Pathol, 32, 1780, 10.1097/PAS.0b013e31818649ed Rohan, 2011, Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins, Mod Pathol, 24, 1207, 10.1038/modpathol.2011.80 Kuroda, 2014, Clear cell papillary renal cell carcinoma: a review, Int J Clin Exp Pathol, 7, 7312 Mantilla, 2017, GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics, Hum Pathol, 66, 152, 10.1016/j.humpath.2017.06.016 Deml, 2015, Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma, Am J Surg Pathol, 39, 889, 10.1097/PAS.0000000000000456 Xu, 2019, Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma, Elife, 8, e38986, 10.7554/eLife.38986 Argani, 2001, Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents, Am J Pathol, 159, 179, 10.1016/S0002-9440(10)61684-7 Argani, 2016, TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers, Am J Surg Pathol, 40, 723, 10.1097/PAS.0000000000000631 Xia, 2018, Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH, Histopathology, 72, 786, 10.1111/his.13439 Williamson, 2020, Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer, Am J Surg Pathol, 44, e47, 10.1097/PAS.0000000000001476 Camparo, 2008, Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature, Am J Surg Pathol, 32, 656, 10.1097/PAS.0b013e3181609914 Classe, 2017, Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas, Histopathology, 70, 1089, 10.1111/his.13167 Tretiakova, 2019, Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features, Genes Chromosomes Cancer, 59, 40, 10.1002/gcc.22798 Argani, 2015, MiT family translocation renal cell carcinoma, Semin Diagn Pathol, 32, 103, 10.1053/j.semdp.2015.02.003 Argani, 2009, Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma, Am J Surg Pathol, 33, 609, 10.1097/PAS.0b013e31818fbdff Inamura, 2017, Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features, Cancers (Basel), 9, 111, 10.3390/cancers9090111 Argani, 2017, RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH, Am J Surg Pathol, 41, 655, 10.1097/PAS.0000000000000835 Xia, 2017, Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement, Mod Pathol, 30, 416, 10.1038/modpathol.2016.204 Ellis, 2014, Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage, Mod Pathol, 27, 875, 10.1038/modpathol.2013.208 Wang, 2017, SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion, Hum Pathol, 63, 190, 10.1016/j.humpath.2017.02.022 Wang, 2018, RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations, Mod Pathol, 31, 1346, 10.1038/s41379-018-0051-5 Pflueger, 2013, Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing, Neoplasia, 15, 1231, 10.1593/neo.131544 Damayanti, 2018, Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma, Clin Cancer Res, 24, 5977, 10.1158/1078-0432.CCR-18-0269 Argani, 2012, Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum, Am J Surg Pathol, 36, 1516, 10.1097/PAS.0b013e3182613d8f Kauffman, 2014, Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers, Nat Rev Urol, 11, 465, 10.1038/nrurol.2014.162 Linehan, 2016, Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma, N Engl J Med, 374, 135, 10.1056/NEJMoa1505917 Qu, 2017, TFEB amplification renal cell carcinoma detected by chromosome genomic array testing: a case report for diagnosis of a novel entity, J Clin Molec Pathol, 1, 07 Williamson, 2017, Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis?, Am J Surg Pathol, 41, 287, 10.1097/PAS.0000000000000776 Gupta, 2017, TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management, Mod Pathol, 30, 998, 10.1038/modpathol.2017.24 Durinck, 2015, Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes, Nat Genet, 47, 13, 10.1038/ng.3146 Tickoo, 2011, Differential diagnosis of renal tumors with papillary architecture, Adv Anat Pathol, 18, 120, 10.1097/PAP.0b013e31820cb3dd Tretiakova, 2004, Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma, Am J Surg Pathol, 28, 69, 10.1097/00000478-200401000-00007 Kinney, 2015, Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma, Mod Pathol, 28, 1236, 10.1038/modpathol.2015.81 Klatte, 2009, Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma, Clin Cancer Res, 15, 1162, 10.1158/1078-0432.CCR-08-1229 Kovac, 2015, Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution, Nat Commun, 6, 6336, 10.1038/ncomms7336 Schmidt, 1999, Novel mutations of the MET proto-oncogene in papillary renal carcinomas, Oncogene, 18, 2343, 10.1038/sj.onc.1202547 Fay, 2014, MET as a target in papillary renal cell carcinoma, Clin Cancer Res, 20, 3361, 10.1158/1078-0432.CCR-14-0690 Courthod, 2015, Papillary renal cell carcinoma: A review of the current therapeutic landscape, Crit Rev Oncol Hematol, 96, 100, 10.1016/j.critrevonc.2015.05.008 Warrick, 2014, Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations, Hum Pathol, 45, 1139, 10.1016/j.humpath.2014.02.004 Cornejo, 2015, Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome, Hum Pathol, 46, 1411, 10.1016/j.humpath.2015.07.001 Bigot, 2016, The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery, World J Urol, 34, 347, 10.1007/s00345-015-1634-0 Amin, 2009, Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm, Am J Surg Pathol, 33, 393, 10.1097/PAS.0b013e31818cb8f5 Tretiakova, 2020, Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor, Int J Surg Pathol, 28, 80, 10.1177/1066896919863478 Jenkins, 2019, Thyroid-Like Follicular Carcinoma of the Kidney With Extensive Sarcomatoid Differentiation: A Case Report and Review of the Literature, Int J Surg Pathol, 27, 678, 10.1177/1066896919845490 Dawane, 2015, Thyroid-like follicular carcinoma of the kidney: one case report and review of the literature, Am J Clin Pathol, 144, 796, 10.1309/AJCP6P0STAAHOTTG Dhillon, 2011, Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes, Hum Pathol, 42, 146, 10.1016/j.humpath.2010.01.026 Gupta, 2008, Metastatic papillary carcinoma of thyroid masquerading as a renal tumour, J Clin Pathol, 61, 143, 10.1136/jcp.2007.048249 Jung, 2006, Thyroid follicular carcinoma-like tumor of kidney: a case report with morphologic, immunohistochemical, and genetic analysis, Am J Surg Pathol, 30, 411, 10.1097/01.pas.0000194745.10670.dd Sterlacci, 2008, Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies, Virchows Arch, 452, 91, 10.1007/s00428-008-0600-2 Vicens, 2014, Multimodality imaging of thyroid-like follicular renal cell carcinoma with lung metastases, a new emerging tumor entity, Abdom Imaging, 39, 388, 10.1007/s00261-013-0053-1 Ko, 2018, Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma, Cold Spring Harb Mol Case Stud, 4, a003137, 10.1101/mcs.a003137 Davis, 1995, Renal medullary carcinoma. The seventh sickle cell nephropathy, Am J Surg Pathol, 19, 1, 10.1097/00000478-199501000-00001 Iacovelli, 2015, Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature, Can Urol Assoc J, 9, E172, 10.5489/cuaj.2373 Alvarez, 2015, Renal medullary carcinoma and sickle cell trait: A systematic review, Pediatr Blood Cancer, 62, 1694, 10.1002/pbc.25592 Msaouel, 2019, Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma, Clin Genitourin Cancer, 17, 1, 10.1016/j.clgc.2018.09.005 Gupta, 2012, Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship, Am J Surg Pathol, 36, 1265, 10.1097/PAS.0b013e3182635954 Liu, 2013, Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation, Am J Surg Pathol, 37, 368, 10.1097/PAS.0b013e3182770406 Cheng, 2008, Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior, Mod Pathol, 21, 647, 10.1038/modpathol.2008.44 Calderaro, 2016, Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas, Eur Urol, 69, 1055, 10.1016/j.eururo.2015.09.027 Jia, 2019, Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases, Mod Pathol, 32, 1329, 10.1038/s41379-019-0273-1 Rao, 2012, Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall, Am J Surg Pathol, 36, 583, 10.1097/PAS.0b013e3182417d78 Carlo, 2017, Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes, Clin Genitourin Cancer, 15, e987, 10.1016/j.clgc.2017.04.012 Walsh, 2010, Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma, Pediatr Blood Cancer, 55, 1217, 10.1002/pbc.22611 Amjad, 2014, Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy, Case Rep Oncol Med, 2014, 615895 Fleming, 1986, Collecting duct carcinoma of the kidney, Histopathology, 10, 1131, 10.1111/j.1365-2559.1986.tb02553.x Kobayashi, 2008, Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis, Hum Pathol, 39, 1350, 10.1016/j.humpath.2007.11.020 Osunkoya, 2009, Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney, Am J Surg Pathol, 33, 1103, 10.1097/PAS.0b013e3181a13e7b Albadine, 2010, PAX8 (+)/p63 (–) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract, Am J Surg Pathol, 34, 965, 10.1097/PAS.0b013e3181dc5e8a Becker, 2013, Collecting duct carcinomas represent a unique tumor entity based on genetic alterations, PLoS One, 8, e78137, 10.1371/journal.pone.0078137 Pal, 2016, Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling, Eur Urol, 70, 516, 10.1016/j.eururo.2015.06.019 Wright, 2009, Effect of collecting duct histology on renal cell cancer outcome, J Urol, 182, 2595, 10.1016/j.juro.2009.08.049 Dason, 2013, Management of renal collecting duct carcinoma: a systematic review and the McMaster experience, Curr Oncol, 20, e223, 10.3747/co.20.1230 Malouf, 2016, Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas, Sci Rep, 6, 30988, 10.1038/srep30988 Watanabe, 2019, Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney, Int Cancer Conf J, 9, 32, 10.1007/s13691-019-00389-z Kuroda, 2005, Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects, Histol Histopathol, 20, 221 Paner, 2006, Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution, Am J Surg Pathol, 30, 13, 10.1097/01.pas.0000180443.94645.50 Ferlicot, 2005, Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature, Virchows Arch, 447, 978, 10.1007/s00428-005-0036-x Kuroda, 2008, Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study, Histol Histopathol, 23, 1517 Dhillon, 2009, Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change, Am J Surg Pathol, 33, 44, 10.1097/PAS.0b013e3181829ed5 Peckova, 2015, Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of low-grade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma, Ann Diagn Pathol, 19, 226, 10.1016/j.anndiagpath.2015.04.004 Sadimin, 2017, Chromosomal abnormalities of high-grade mucinous tubular and spindle cell carcinoma of the kidney, Histopathology, 71, 719, 10.1111/his.13298 Ren, 2018, Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney from Papillary Renal Cell Carcinoma With Overlapping Histologic Features, Am J Surg Pathol, 42, 767, 10.1097/PAS.0000000000001038 Bulimbasic, 2009, Aggressive high-grade mucinous tubular and spindle cell carcinoma, Hum Pathol, 40, 906, 10.1016/j.humpath.2009.03.004 Larkin, 2010, Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib, J Clin Oncol, 28, e539, 10.1200/JCO.2010.30.1457 Ursani, 2011, Mucinous tubular and spindle cell carcinoma of kidney without sarcomatoid change showing metastases to liver and retroperitoneal lymph node, Hum Pathol, 42, 444, 10.1016/j.humpath.2010.07.018 Amin, 1997, Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases, Am J Surg Pathol, 21, 1, 10.1097/00000478-199701000-00001 Trpkov, 2010, Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features, Histopathology, 57, 893, 10.1111/j.1365-2559.2010.03726.x Perez-Ordonez, 1997, Renal oncocytoma: a clinicopathologic study of 70 cases, Am J Surg Pathol, 21, 871, 10.1097/00000478-199708000-00001 Hes, 2008, Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical and genetic features, Virchows Arch, 452, 285, 10.1007/s00428-007-0564-7 Wobker, 2016, Renal oncocytoma with vascular invasion: a series of 22 cases, Hum Pathol, 58, 1, 10.1016/j.humpath.2016.07.020 Wobker, 2017, Modern Pathologic Diagnosis of Renal Oncocytoma, J Kidney Cancer VHL, 4, 1, 10.15586/jkcvhl.2017.96 Williamson, 2017, Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists, Hum Pathol, 63, 149, 10.1016/j.humpath.2017.03.004 Liu, 2020, Sporadic Oncocytic Tumors with Features Intermediate between Oncocytoma and Chromophobe Renal Cell Carcinoma: Comprehensive Clinico-Pathological and Genomic Profiling, Hum Pathol, 10.1016/j.humpath.2020.07.003 Hes, 2007, Vimentin reactivity in renal oncocytoma: immunohistochemical study of 234 cases, Arch Pathol Lab Med, 131, 1782, 10.5858/2007-131-1782-VRIROI Sukov, 2009, CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma, Hum Pathol, 40, 1296, 10.1016/j.humpath.2009.01.016 Joshi, 2015, The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis, Cell Rep, 13, 1895, 10.1016/j.celrep.2015.10.059 Anderson, 2019, Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations, Genes Chromosomes Cancer, 59, 6, 10.1002/gcc.22766 Hes, 2013, Renal hybrid oncocytic/chromophobe tumors - a review, Histol Histopathol, 28, 1257 Gill, 2010, Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes, Hum Pathol, 41, 805, 10.1016/j.humpath.2009.12.005 Gill, 2011, Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4, N Engl J Med, 364, 885, 10.1056/NEJMc1012357 Gill, 2018, Succinate dehydrogenase (SDH)-deficient neoplasia, Histopathology, 72, 106, 10.1111/his.13277 Gill, 2014, Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients, Am J Surg Pathol, 38, 1588, 10.1097/PAS.0000000000000292 Benn, 2018, Bayesian approach to determining penetrance of pathogenic SDH variants, J Med Genet, 55, 729, 10.1136/jmedgenet-2018-105427 Gill, 2011, Renal tumors associated with germline SDHB mutation show distinctive morphology, Am J Surg Pathol, 35, 1578, 10.1097/PAS.0b013e318227e7f4 Gill, 2012, Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia, Pathology, 44, 285, 10.1097/PAT.0b013e3283539932 Ricketts, 2012, Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer, J Urol, 188, 2063, 10.1016/j.juro.2012.08.030 Williamson, 2015, Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma, Mod Pathol, 28, 80, 10.1038/modpathol.2014.86 van Nederveen, 2009, An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis, Lancet Oncol, 10, 764, 10.1016/S1470-2045(09)70164-0 Korpershoek, 2011, SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas, J Clin Endocrinol Metab, 96, E1472, 10.1210/jc.2011-1043 Azoulay, 2007, Tubulocystic carcinoma of the kidney: a new entity among renal tumors, Virchows Arch, 451, 905, 10.1007/s00428-007-0483-7 Yang, 2008, Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization, Am J Surg Pathol, 32, 177, 10.1097/PAS.0b013e318150df1d Amin, 2009, Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma, Am J Surg Pathol, 33, 384, 10.1097/PAS.0b013e3181872d3f Zhou, 2009, Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification, Am J Surg Pathol, 33, 1840, 10.1097/PAS.0b013e3181be22d1 Tran, 2016, Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma, Histopathology, 68, 850, 10.1111/his.12840 Lawrie, 2018, Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms, J Mol Diagn, 20, 34, 10.1016/j.jmoldx.2017.09.002 Sarungbam, 2019, Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile, Mod Pathol, 32, 701, 10.1038/s41379-018-0185-5 Smith, 2016, Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma, Am J Surg Pathol, 40, 1457, 10.1097/PAS.0000000000000719 Yang, 2006, Classification of renal neoplasms based on molecular signatures, J Urol, 175, 2302, 10.1016/S0022-5347(06)00255-2 Marsaud, 2015, Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases, Genes Chromosomes Cancer, 54, 369, 10.1002/gcc.22248 Alaghehbandan, 2019, Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach, Cancers (Basel), 12, 85, 10.3390/cancers12010085 Saleeb, 2017, Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis, Am J Surg Pathol, 41, 1618, 10.1097/PAS.0000000000000962 Al-Obaidy, 2019, Papillary Renal Neoplasm with Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study, Am J Surg Pathol, 43, 1099, 10.1097/PAS.0000000000001288 Kim, 2020, Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma, Mod Pathol, 33, 690, 10.1038/s41379-019-0420-8 Chevarie-Davis, 2014, The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features, Am J Surg Pathol, 38, 887, 10.1097/PAS.0000000000000247 Alomari, 2015, Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping, Hum Pathol, 46, 1418, 10.1016/j.humpath.2015.06.006 Pitra, 2019, Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article, Ann Diagn Pathol, 40, 189, 10.1016/j.anndiagpath.2017.11.004 Launonen, 2001, Inherited susceptibility to uterine leiomyomas and renal cell cancer, Proc Natl Acad Sci U S A, 98, 3387, 10.1073/pnas.051633798 Kiuru, 2002, Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families, Cancer Res, 62, 4554 Merino, 2007, The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, Am J Surg Pathol, 31, 1578, 10.1097/PAS.0b013e31804375b8 Trpkov, 2016, Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated with Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome, Am J Surg Pathol, 40, 865, 10.1097/PAS.0000000000000617 Kiuru, 2001, Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology, Am J Pathol, 159, 825, 10.1016/S0002-9440(10)61757-9 Ohe, 2018, Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma, Am J Surg Pathol, 42, 279, 10.1097/PAS.0000000000001000 Lau, 2020, A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients, Am J Surg Pathol, 44, 98, 10.1097/PAS.0000000000001372 Chen, 2014, Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry, Am J Surg Pathol, 38, 627, 10.1097/PAS.0000000000000163 Muller, 2018, Mod Pathol, 31, 974, 10.1038/s41379-018-0017-7 Muller, 2017, Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers, Clin Genet, 92, 606, 10.1111/cge.13014 Michalova, 2018, Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases, Ann Diagn Pathol, 35, 1, 10.1016/j.anndiagpath.2018.01.010 Trpkov, 2018, Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases, Histopathology, 72, 777, 10.1111/his.13432 Nouh, 2010, Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis, BJU Int, 105, 620, 10.1111/j.1464-410X.2009.08817.x Przybycin, 2018, Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC): A Multiinstitutional Study of 40 Cases with Clinical Follow-up, Am J Surg Pathol, 42, 1156, 10.1097/PAS.0000000000001091 Sule, 2005, Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study, Am J Surg Pathol, 29, 443, 10.1097/01.pas.0000152131.58492.97 Rioux-Leclercq, 2003, Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney, Arch Pathol Lab Med, 127, E89, 10.5858/2003-127-e89-RCCWIC Pan, 2009, Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma, Histopathology, 55, 145, 10.1111/j.1365-2559.2009.03361.x Kojima, 2020, Comprehensive Clinicopathologic Analyses of Acquired Cystic Disease-associated Renal Cell Carcinoma With Focus on Adverse Prognostic Factors and Metastatic Lesions, Am J Surg Pathol, 44, 1031, 10.1097/PAS.0000000000001482 Cheuk, 2002, Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations, Hum Pathol, 33, 761, 10.1053/hupa.2002.125370 Kuroda, 2011, Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features, Ann Diagn Pathol, 15, 462, 10.1016/j.anndiagpath.2010.07.008 Kuntz, 2010, Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease, Hum Pathol, 41, 1345, 10.1016/j.humpath.2009.09.022 Debelenko, 2011, Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum, Mod Pathol, 24, 430, 10.1038/modpathol.2010.213 Smith, 2014, VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?, Am J Surg Pathol, 38, 858, 10.1097/PAS.0000000000000179 Siadat, 2020, ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification, Cancers (Basel), 12, 168, 10.3390/cancers12010168 Kuroda, 2020, ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217, Mod Pathol, 1 Kusano, 2016, Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene, Am J Surg Pathol, 40, 761, 10.1097/PAS.0000000000000610 Bodokh, 2018, ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review, Cancer Genet, 221, 31, 10.1016/j.cancergen.2017.11.010 Yu, 2017, Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review, Histopathology, 71, 53, 10.1111/his.13185 Sugawara, 2012, Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method, Cancer, 118, 4427, 10.1002/cncr.27391 Cajaiba, 2016, ALK-rearranged renal cell carcinomas in children, Genes Chromosomes Cancer, 55, 442, 10.1002/gcc.22346 Sukov, 2012, ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients, Mod Pathol, 25, 1516, 10.1038/modpathol.2012.107 Kuroda, 2018, A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects, Pol J Pathol, 69, 109, 10.5114/pjp.2018.76693 Pal, 2018, Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma, Eur Urol, 74, 124, 10.1016/j.eururo.2018.03.032